## IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

ASTRAZENECA AB,	X :
Plaintiff,	: : C.A. No
v.	
MYLAN PHARMACEUTICALS, INC.,	
Defendant.	:
	: : X
SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)	
Plaintiffs hereby provide the information	below with respect to the deadlines set forth in
21 U.S.C. § 355(j):	
Date Patentee(s) Received Notice:	No earlier than April 30, 2014
Date of Expiration of Patent:	7,951,400 (November 30, 2028) RE44,186 (July 31, 2023) 8,628,799 (July 13, 2025)
Thirty Month Stay Deadline:	No earlier than October 31, 2016
DATED: June 2, 2014	MCCARTER & ENGLISH, LLP
	/s/ Michael P. Kelly Michael P. Kelly (#2295) Daniel M. Silver (#4758) Renaissance Centre 405 N. King Street, 8th Floor Wilmington, Delaware 19801 (302) 984-6300 mkelly@mccarter.com dsilver@mccarter.com

Attorneys for Plaintiff AstraZeneca AB